Lipid offers new ways of treating inflammatory kidney diseases

Aug 29 2007

Scientists report in the September 2007 issue of the Journal of Lipid Research that a lipid known to protect the heart from inflammation and to cause skin allergic reactions also reduces inflammation of the kidneys.

The discovery could help devise new ways of treating inflammatory kidney diseases.

The lipid, called sphingosylphosphorylcholine (SPC), has been shown to cause an increase in urine production in the kidneys and an abnormal accumulation of salt in the urine. But how SPC works in the kidneys is not completely understood.

Andrea Huwiler and colleagues examined the various proteins activated by SPC in kidney cells and showed for the first time that SPC triggers proteins known to reduce inflammation. Although more details will be needed to understand how these proteins and how SPC may interact with other anti-inflammatory proteins – such as transforming growth factor beta – SPC may be useful in the treatment of chronic inflammatory and fibrotic diseases of the kidneys, the scientists concluded.

Article: “Sphingosylphosphorylcholine acts in an anti-inflammatory manner in renal mesangial cells by reducing interleukin-1b-induced prostaglandin E2 formation ,” by Cuiyan Xin, Shuyu Ren, Wolfgang Eberhardt, Josef Pfeilschifter, and Andrea Huwiler.